skin gametop rux clear
topic ruxolitinib met primari endpoint iga treatment success second
posit top-line jan nda submiss expect late overal efficaci
safeti profil consist previou data topic rux show
placebo-adjust iga respons week eight bid
bid exhibit p-valu across board underlin result
believ efficaci topic cream appeal ad patient data show efficaci
topic rux approach level certain system therapi dupilumab upadacitinib
although patient popul differ better side effect profil increas
pt base trial result
compar ruxolitinib cream vs vehicl patient age year
ad studi continu deliv long-term safeti data
requir file second ident trial posit toplin jan
nda submiss expect late collect
month long-term safeti data on-going
true-ad studi two dose bid bid vs vehicl
overal efficaci safeti profil consist previou data topic
rux show placebo-adjust iga respons week eight
bid bid exhibit p-valu across
board underlin result result trial consist placebo-
patient show least improv easi score vs bl
placebo-adjust bid bid
believ efficaci topic cream appeal ad patient
progress system therapi potenti delay use system
data show efficaci topic rux approach level certain system therapi
dupilumab upadacitinib although patient popul differ better side
effect profil recent announc posit top-line
oral baracitinib vs topic steroid mod-sev ad topic rux iga
respons rate mild-mod ad approach oral option rang
view studi first win support push dermatolog
long-term safeti data allow us file ye look
partner topic rux row ex-eu option tabl eu
maintain outperform rate increas pt increas
po topic rux
year price histori incyt
biopharma compani
focus small molecul oncolog
jakafi
analyst certif import disclosur see disclosur
jakafi success commerci gvhd
topic ruxolotinib approv dermatolog condit
accret invest cash rel low-risk pipelin asset
inhibitor signific potenti myelofibrosi mf
polycythemia vera pv potenti indic
clinic investig deep promis pipelin
includ capmatinib divers pipelin drive
acceler revenu growth current under-valu
view
result ruxolitinib cream
potenti fda approv pemigatinib cca
poc data mf
file tafasitamab dlbcl
potenti fda approv tafasitamab dlbcl
result ruxolitinib sr-cgvhd
potenti fda approv capmatinib nsclc
nda file ruxolitinib cream atop dermat
initi mf
result itacitinib sn-cgvhd
higher expect sale market product
greater expect advanc pipelin asset
pipelin asset fail differenti offer strateg advantag
collabor
price target per share base dcf valuat methodolog employ wacc termin growth rate
view appropri compani commerci asset clinical-stag pipelin estim jakafi sale could
peak us includ peak royalti ex-u sale see iclusig olumi smaller contributor
revenu
key known downsid risk price target clinic develop risk regulatori risk pipelin addit risk come
build commerci infrastructur indic higher anticip competit drug develop
upsid risk includ acquisit signific premium better expect clinic data drug pipelin
exhibit true-ad studi two dose bid bid
vs vehicl overal efficaci safeti profil consist
week bid bid
patient show least improv easi score vs bl
placebo-adjust bid
bid data show efficaci topic rux approach level certain
popul differ better side effect profil
exhibit hypothet sotp valuat
exhibit dcf valuat increas pt
increas po topic rux
drug/indicationexpect launchpeak sale estim mm estimate probabl successnpv mm p-adj npv mm p-adj valu sharejakafi pipelin asset fgfr pipelin asset invest equiti share outstand use valuat oppenheim co incyt discount analysisoppenheim co except per-shar data revenu chang work work capit valu growth valu valu per sharetermin valu growth rate outperform
thousand except per share
product royalti revenu olumi us eu row
probabl success
probabl success
probabl success
probabl success
probabl success
mileston contract research
probabl success
licens royalti
cost expens
good sold royalti jakafi
good sold amortizatin iclusig right eu
good sold small mol
good sold biolog
amort acquir product right
share-bas compens cog
share-bas compens cog expens
research develop
adjust research develop non-gaap
up-front consider collabor
share-bas compens
share-bas compens expens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
share-bas compens sg expens
incom loss oper
incom expens
interest incom expens net
loss debt repurchas
unreal gain long term invest
ep basic dilut
ep non-gaap basic dilut
share use comput ep basic
share use comput ep dilut
fulli dilut share out use valuat
co nyse cover
